- Record Avenova® sales
of $2.6 million
- Gross margin improved to
82%
- Cash burn from operations reduced
approximately 50% from Q1 2016
- Affirms outlook to reach positive
cash flow from operations in December 2016
Conference call begins today at 4:30 p.m.
Eastern time
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a
biopharmaceutical company focusing on commercializing its
prescription Avenova lid and lash hygiene product for the domestic
eye care market, reports financial results for the three and six
months ended June 30, 2016, and provides a business update.
“NovaBay achieved record Avenova sales of $2.6 million,
representing a healthy 89% growth over first quarter and over a $10
million annualized run rate. We drove these gains by our focused
execution on the higher margin prescription ophthalmology channel,”
said Mark M. Sieczkarek, NovaBay’s President and CEO. “Our gross
margin continues to expand as we increase our sales in this
reimbursed channel. These improvements, in combination with the
actions we took late last year to restructure the Company and
reduce operating expenses, has lowered our cash burn by nearly
50%.
“Importantly, Avenova has yet to scratch the surface of the
market opportunity we estimate at about 41 million Americans,” said
Mr. Sieczkarek. “I’m pleased to report NovaBay still is on track to
achieve our goal of positive adjusted cash flow from operations in
December 2016.”
NovaBay defines adjusted cash flow from operations as GAAP cash
flow from operations less changes in operating assets and
liabilities.
Key Second Quarter Avenova Metrics (all comparisons from
the first quarter of 2016)
- Total Avenova sales increased to $2.6
million, up 89%
- Prescription sales into the pharmacy
channel increased to $1.7 million, up 201%
- Over 1,100 new prescribers added in the
second quarter
- Total number of medical professionals
who have prescribed Avenova increased 12%
Second Quarter 2016 Financial Results
Net sales for the second quarter of 2016 were $2.7 million, up
164% from $1.0 million for the second quarter of 2015. Product
revenue, which includes sales of Avenova and NeutroPhase®,
increased 185% to $2.7 million. Total gross profit margin was 82%
for the second quarter of 2016, compared with 75% for the
prior-year period, with the increase mainly due to higher sales of
Avenova. The gross profit margin on Avenova sales grew to 85%.
Operating loss for the second quarter of 2016 was $2.2 million,
representing improvements of 55% from $4.9 million reported for the
second quarter of 2015 and 52% from the first quarter of 2016.
R&D expenses for the second quarter of 2016 decreased by 80% to
$278,000 from $1.4 million for the second quarter of 2015 and by
70% from the first quarter of 2016, primarily due to lower spending
on clinical trials that were completed. G&A expenses for the
second quarter of 2016 decreased by 35% to $1.3 million from $1.9
million for the prior-year period and by 24% from the first quarter
of 2016, primarily due to overall cost reduction efforts including
reductions in staff-related expenses, stock-based compensation
expense and consulting and outside services. Sales and marketing
expenses for the second quarter of 2016 increased by 23% to $2.9
from $2.3 million for the second quarter of 2015, primarily due to
the focus on the commercialization of Avenova, and were down by 9%
from the first quarter of 2016.
Non-cash loss on the change of fair value of warrant liability
for the three month ended June 30, 2016 was $424,000, compared with
no adjustment for the three months ended June 30, 2015.
The net loss for the second quarter of 2016 was $2.7 million, or
$0.36 per share, compared with a net loss for the second quarter of
2015 of $4.9 million, or $1.84 per share. The net loss for the
second quarter of 2016 declined by $2.4 million or 47% from the
first quarter of 2016.
Six-Month 2016 Financial Results
Net sales for the six months ended June 30, 2016 were $4.4
million, up 183% from $1.5 million for the six months ended June
30, 2015, with the increase primarily attributable to significantly
higher sales of Avenova. Product revenue for the first half of 2016
increased 203% to $4.3 million. Gross profit margin was 75% the
first half of 2016, compared with 74% for the first half of 2015.
Gross profit margin on the Avenova brand was 82% the first half of
2016.
Operating loss for the first six months of 2016 was $6.8
million, a 28% improvement from $9.5 million for the comparable
period in 2015. R&D expenses for the first six months of 2016
were $1.2 million, a decrease of 59% from the prior-year period,
and G&A expenses were $2.9 million, a decrease of 17% from the
prior -year period. Sales and marketing expenses for the six months
ended June 30, 2016 were $6.0 million, an increase of 42% from the
prior-year period.
Non-cash loss on the change of fair value of warrant liability
for the first six months of 2016 was $809,000, compared with a gain
of $34,000 for the first six months of 2015.
The net loss for the six months ended June 30, 2016 was $7.8
million, or $1.35 per share, compared with a net loss for the six
months ended June 30, 2015 of $9.5 million, or $3.94 per share.
NovaBay reported cash of $3.5 million as of June 30, 2016,
compared with $2.4 million as of December 31, 2015. In May 2016,
the Company closed the first tranche of a financing for gross
proceeds of $7.8 million. On August 1, 2016, the Company closed the
second and final tranche of the financing for gross proceeds of
$4.0 million.
The Company used approximately $2.7 million in cash to fund
operations during the second quarter of 2016, compared with $5.4
million used during the second quarter of 2015, with the decrease
primarily due to higher gross profit from Avenova sales and lower
operating expenses achieved through company-wide cost reduction
programs.
Conference Call
NovaBay management will host an investment community conference
call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific
time) to discuss the Company’s financial and operational results,
and to answer questions. Shareholders and other interested parties
may participate in the conference call by dialing 800-608-8202 from
within the U.S. or 702-495-1913 from outside the U.S., with the
conference identification number 54133101.
A live webcast of the call will be available at
http://novabay.com/investors/events and will be archived for 90
days.
A replay of the call will be available beginning two hours after
call completion through 11:59 p.m. Eastern time August 15, 2016, by
dialing 855-859-2056 from within the U.S. or 404-537-3406 from
outside the U.S. and entering the conference identification number
54133101
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing
on the commercialization of prescription Avenova® lid and lash
hygiene for the eye care market. Avenova is formulated with
Neutrox™, which is cleared by the U.S. Food and Drug Administration
(FDA) as a 510(k) medical device. Neutrox is NovaBay’s pure
hypochlorous acid. Laboratory tests show that pure hypochlorous
acid has potent antimicrobial activity in solution yet is non-toxic
to mammalian cells and it also neutralizes bacterial toxins. Data
from a multicenter clinical study show that Avenova reduced
bacterial load, the underlying cause of blepharitis, on ocular skin
surface by more than 90%. Avenova is marketed to optometrists and
ophthalmologists throughout the U.S. by NovaBay’s direct medical
salesforce. It is accessible from more than 90% of retail
pharmacies in the U.S. through agreements with McKesson
Corporation, Cardinal Health and AmeriSource Bergen.
Forward-Looking Statements
This release contains forward-looking statements, which are
based upon management's current expectations, assumptions,
estimates, projections and beliefs. These statements include,
but are not limited to, statements regarding our ability to become
cash flow positive by the end of 2016, future sales of our
products, the ability to raise additional capital through warrant
exercises, and the Company’s expected future financial results.
Forward-looking statements can be identified with words like (and
variations of): “estimate,” “believe,” and “expect.” These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to difficulties or delays in
manufacturing, distributing, and selling the Company's products,
unexpected adverse side effects or inadequate therapeutic efficacy
of our product, the uncertainty of patent protection for the
Company's intellectual property, and the Company's ability to
obtain additional financing as necessary. Other risks relating
to NovaBay’s business, including risks that could cause results to
differ materially from those projected in the forward-looking
statements in this press release, are detailed in NovaBay's latest
Form 10-K and Form 10-Q filings with the Securities and Exchange
Commission, especially under the heading "Risk Factors." The
forward-looking statements in this release speak only as of this
date, and NovaBay disclaims any intent or obligation to revise or
update publicly any forward-looking statement except as required by
law.
Stay informed on NovaBay's
progress:Download our Mobile InvestorApp from
the Apple Store or Google PlayLike us
on FacebookFollow us on TwitterConnect
with NovaBay on LinkedInJoin us on
Google+Visit NovaBay's Website
NOVABAY PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED
BALANCE SHEETS (Unaudited) (In thousands, except per
share data) June 30, December
31, 2016 2015
ASSETS Current assets: Cash $ 3,495 $ 2,385 Accounts
receivable, net of allowance for doubtful accounts ($22 and $40 at
June 30, 2016 and December 31, 2015, respectively) 1,490 536
Inventory, net of allowance for obsolete inventory and lower cost
of market ($37 and $45 at June 30, 2016 and December 31, 2015,
respectively) 1,115 1,345 Prepaid expenses and other current assets
474 261 Total current assets 6,574
4,527 Property and equipment, net 366 395 Other assets 65
155 TOTAL ASSETS $ 7,005 $ 5,077
LIABILITIES AND STOCKHOLDERS' (DEFICIT) Liabilities:
Current liabilities: Accounts payable $ 860 $ 2,483 Accrued
liabilities 1,915 1,980 Deferred revenue 1,593
170 Total current liabilities 4,368 4,633 Deferred revenues
- non-current 2,132 2,248 Deferred rent 189 189 Notes payable,
related party 524 1,655 Warrant liability 2,259
1,450 Total liabilities 9,472
10,175 Stockholders' (deficit): Common stock, $0.01
par value; 240,000,000 shares authorized; 9,156,935 and 3,486,232
shares issued and outstanding at June 30, 2016 and December 31,
2015, respectively 92 35 Additional paid-in capital 95,728 85,387
Accumulated deficit (98,287 ) (90,520 ) Total
stockholders' (deficit) (2,467 ) (5,098 ) TOTAL
LIABILITIES AND STOCKHOLDERS' DEFICIT $ 7,005 $ 5,077
NOVABAY PHARMACEUTICALS, INC. CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited) (In thousands, except per share data)
Three Months Ended
Six Months Ended
June 30,
June 30, 2016 2015 2016
2015 Sales: Product
revenue $ 2,654 $ 931 $ 4,309 $ 1,423 Other revenue 9
77 73 123 Total net sales
2,663 1,008 4,382 1,546 Product cost of goods sold
479 253 1,090 401
Gross profit 2,184 755 3,292
1,145 Research and development 278
1,357 1,211 2,940 Sales and marketing 2,853 2,311 5,997 4,225
General and administrative 1,258 1,946
2,913 3,500 Total operating expenses
4,389 5,614 10,121
10,665 Operating Loss (2,205 ) (4,859 ) (6,829 ) (9,520 )
Non cash (loss) gain on changes in fair value of warrant
liability (424 ) - (809 ) 34 Other expense, net (59 )
(22 ) (127 ) (33 ) Loss before provision for
income taxes (2,688 ) (4,881 ) (7,765 ) (9,519 ) Provision for
income tax (2 ) (6 ) (2 ) (8 ) Net loss
and comprehensive loss $ (2,690 ) $ (4,887 ) $ (7,767 ) $ (9,527 )
Net loss per share attributable to common stock (basic and
diluted) $ (0.36 ) $ (1.84 ) $ (1.35 ) $ (3.94 )
Weighted-average shares of common stock outstanding used in
computing net loss per share of common stock 7,406,605 2,653,226
5,746,314 2,415,361
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160811006012/en/
NovaBay ContactsFor NovaBay
Avenova purchasing information, please contact:Email usCall us:
1-800-890-0329www.Avenova.comorFrom the
CompanyThomas J. PaulsonChief Financial
Officer510-899-8809Contact TomorInvestor
ContactLHAJody Cain310-691-7100Jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024